Bio-Rad Laboratories Inc (NYSE:BIO-B) — Market Cap & Net Worth
Market Cap & Net Worth: Bio-Rad Laboratories Inc (BIO-B)
Bio-Rad Laboratories Inc (NYSE:BIO-B) has a market capitalization of $1.85 Billion ($1.85 Billion) as of September 17, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #6453 globally and #2048 in its home market, demonstrating a 8.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bio-Rad Laboratories Inc's stock price $365.08 by its total outstanding shares 5061038 (5.06 Million). Also see Bio-Rad Laboratories Inc asset portfolio for a full breakdown of the balance sheet.
Bio-Rad Laboratories Inc Market Cap History: 2015 to 2026
Bio-Rad Laboratories Inc's market capitalization history from 2015 to 2026. Data shows growth from $696.80 Million to $1.85 Billion (9.18% CAGR). Also see Bio-Rad Laboratories Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Bio-Rad Laboratories Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bio-Rad Laboratories Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BIO-B live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.49x
Bio-Rad Laboratories Inc's market cap is 0.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.67x
Bio-Rad Laboratories Inc's market cap is 1.67 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $926.93 Million | $2.07 Billion | $28.12 Million | 0.45x | 32.96x |
| 2017 | $1.21 Billion | $2.16 Billion | $114.74 Million | 0.56x | 10.51x |
| 2018 | $1.16 Billion | $2.29 Billion | $361.00 Million | 0.51x | 3.22x |
| 2019 | $1.87 Billion | $2.31 Billion | $1.76 Billion | 0.81x | 1.06x |
| 2020 | $2.91 Billion | $2.55 Billion | $3.81 Billion | 1.14x | 0.76x |
| 2021 | $3.66 Billion | $2.92 Billion | $4.25 Billion | 1.25x | 0.86x |
| 2022 | $2.05 Billion | $2.80 Billion | -$3.63 Billion | 0.73x | N/A |
| 2023 | $1.62 Billion | $2.67 Billion | -$637.32 Million | 0.61x | N/A |
| 2024 | $1.65 Billion | $2.57 Billion | -$1.84 Billion | 0.64x | N/A |
| 2025 | $1.27 Billion | $2.58 Billion | $759.90 Million | 0.49x | 1.67x |
Competitor Companies of BIO-B by Market Capitalization
Companies near Bio-Rad Laboratories Inc in the global market cap rankings as of September 17, 2026. Review how tangible is Bio-Rad Laboratories Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bio-Rad Laboratories Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.42 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #232 globally with a market cap of $107.98 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.42 Billion | $102.03 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $93.75 |
| #232 | Stryker Corporation | NYSE:SYK | $107.98 Billion | $281.50 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Bio-Rad Laboratories Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Bio-Rad Laboratories Inc's market cap moved from $696.80 Million to $ 1.85 Billion, with a yearly change of 9.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.85 Billion | +45.99% |
| 2025 | $1.27 Billion | -23.19% |
| 2024 | $1.65 Billion | +1.54% |
| 2023 | $1.62 Billion | -20.76% |
| 2022 | $2.05 Billion | -44.02% |
| 2021 | $3.66 Billion | +25.91% |
| 2020 | $2.91 Billion | +55.34% |
| 2019 | $1.87 Billion | +60.70% |
| 2018 | $1.16 Billion | -3.46% |
| 2017 | $1.21 Billion | +30.08% |
| 2016 | $926.93 Million | +33.03% |
| 2015 | $696.80 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Bio-Rad Laboratories Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.85 Billion USD |
| MoneyControl | $1.85 Billion USD |
| MarketWatch | $1.85 Billion USD |
| marketcap.company | $1.85 Billion USD |
| Reuters | $1.85 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, pu… Read more